Fig. 4: AML patients experiencing a richness boost after azacitidine (AZA) treatment display skewed TRBV gene usage. | Blood Cancer Journal

Fig. 4: AML patients experiencing a richness boost after azacitidine (AZA) treatment display skewed TRBV gene usage.

From: Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients

Fig. 4

Principal component analyses (PCA) of TRBV and TRBJ gene usage comparing AML patients with increased T cell repertoire richness after azacitidine to AML patients without immunological response (A, B) revealed TRBV skewing. Similarly, patients with particular diverse T cell repertoires at diagnosis showed differential TRBV (C) and TRBJ gene usage (D).

Back to article page